Do SERMs Favorably Impact Clinical Markers of Cardiovascular Risk? In women, menopause is accompanied by clear changes in serum lipoproteins, [30] and plasma lipoprotein levels are clear predictors of ...

Selective estrogen-receptor (ER) modulators (SERMs) are synthetic nonsteroidal compounds that switch on and switch off target sites throughout the body. Tamoxifen, the pioneering SERM, blocks estrogen ...

S-Phase Fraction and Urokinase Plasminogen Activator Are Better Markers for Distant Recurrences Than Nottingham Prognostic Index and Histologic Grade in a Prospective Study of Premenopausal Lymph Node ...

Athira Pharma has joined an attempt to rescue an asset abandoned by Pfizer. The biotech has secured near-global rights to a phase 3 breast cancer prospect in a deal with Sermonix Pharmaceuticals.

A research paper published today (8 February 2024) in The Lancet Oncology demonstrates that the drug enobosarm, a selective androgen receptor modulator which stimulates the male sex hormone receptor ...

Hormone therapy in older women with breast cancer was associated with a reduced risk of subsequent dementia, a retrospective study of Medicare patients suggested. Breast cancer patients who received ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing innovative medicines for unmet medical needs, today announced that the U.S. Food and Drug Administration ...

Atossa Therapeutics ( ($ATOS) ) has issued an update. On January 6, 2026, Atossa Therapeutics announced that the U.S. Food and Drug Administration ...

Turning to Wall Street, the analysts’ consensus rating for Athira Pharma is Hold, based on a single Hold rating over the past three months. With that comes a $4 price target for ATHA stock, ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, ...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 7, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage ...